Protagenic Therapeutics, Inc.\new Financing Cash Flow
Protagenic Therapeutics, Inc.\new (PTIX) reported Financing Cash Flow of $3.87 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$533.90K, a 620.78% decline year-over-year.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$2.00, a 100.00% decline year-over-year.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$599.28K.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $5.01M, a 420.12% increase year-over-year.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for fiscal 2026 was $3.87M, a 114.10% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for fiscal 2025 was $1.81M.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for fiscal 2024 was $1.96M.
- Protagenic Therapeutics, Inc.\new net cash provided by (used in) financing activities for fiscal 2021 was $12.58M, a 928.08% increase from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$533.90K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-14 | -$533.90K derived: sum of 2 quarters · filed 2026-08-14 | -$1.13M derived: sum of 3 quarters · filed 2026-08-14 | $3.87M 10-K · filed 2026-08-14 | |
| 2025-12-31 | -$2.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | -$599.29K derived: sum of 2 quarters · filed 2026-03-09 | $4.41M 10-Q · filed 2026-03-09 | $4.51M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-09-30 | -$599.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-26 | $4.41M 10-Q · filed 2025-11-26 | $4.51M derived: sum of 3 quarters · filed 2026-08-19 | $5.88M derived: sum of 4 quarters · filed 2026-08-19 | |
| 2025-06-30 | $5.01M 10-Q · filed 2026-08-19 | $4.42M 10-QT · filed 2025-09-10 | $5.11M derived: sum of 2 quarters · filed 2026-08-19 | $6.48M derived: sum of 3 quarters · filed 2026-08-19 | $6.35M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $102.52K 10-Q · filed 2025-05-13 | $1.47M derived: sum of 2 quarters · filed 2026-03-09 | $1.34M derived: sum of 3 quarters · filed 2026-03-09 | $1.81M 10-K · filed 2026-08-14 | |
| 2024-12-31 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-09 | $1.24M derived: sum of 2 quarters · filed 2026-03-09 | $2.20M 10-Q · filed 2026-03-09 | $1.96M 10-K · filed 2025-03-31 | |
| 2024-09-30 | -$129.79K derived: 10-Q 6 month − 10-QT 3 month · filed 2025-11-26 | $832.83K 10-Q · filed 2025-11-26 | $361.49K 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | $962.63K 10-QT · filed 2025-09-10 | $44.53K 10-Q · filed 2024-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $12.45M derived: sum of 3 quarters · filed 2023-03-31 | $12.58M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $12.45M derived: sum of 2 quarters · filed 2022-11-14 | $12.58M 10-Q · filed 2022-11-14 | $12.58M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $12.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $12.58M 10-Q · filed 2022-08-11 | $12.58M derived: sum of 3 quarters · filed 2022-08-11 | $12.90M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $127.13K 10-Q · filed 2022-05-13 | $127.13K derived: sum of 2 quarters · filed 2022-05-13 | $450.54K derived: sum of 3 quarters · filed 2022-05-13 | $1.02M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-07 | $323.41K derived: sum of 2 quarters · filed 2022-04-07 | $893.41K derived: sum of 3 quarters · filed 2022-04-07 | $1.22M 10-K · filed 2022-04-07 | |
| 2020-09-30 | $323.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $893.41K derived: sum of 2 quarters · filed 2021-11-15 | $1.22M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $570.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $900.00K 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | $330.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | $670.00K 10-K · filed 2021-03-25 | ||||
| 2016-12-31 | -$18.50K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$18.50K derived: sum of 2 quarters · filed 2018-04-02 | $486.69K derived: sum of 3 quarters · filed 2018-04-02 | $4.28M 10-K · filed 2018-04-02 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $505.19K derived: sum of 2 quarters · filed 2017-11-13 | $4.30M 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $505.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $4.30M 10-Q · filed 2016-08-15 | |||
| 2016-03-31 | $3.80M 10-Q · filed 2016-07-25 | ||||
| 2015-09-30 | $163.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-17 | $214.15K 10-Q · filed 2016-11-17 | |||
| 2015-06-30 | $50.20K 10-Q · filed 2016-08-15 | ||||
| 2011-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | $4.36M 10-Q · filed 2011-11-14 | |||
| 2011-06-30 | $4.36M 10-Q/A · filed 2011-09-07 | ||||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2011-11-14 | -$9.00K 10-Q · filed 2011-11-14 | |||
| 2010-06-30 | -$9.00K 10-Q/A · filed 2011-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |